Latest Ratios: P/E Ratio 11.5x · EV/EBITDA 7.7x · ROE N/A. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.4B | $6.7B | $3.5B | $2.1B | $2.7B | $2.8B | $4.0B | $2.8B | $1.6B | $654M | $371M |
| Enterprise Value | $6.9B | $6.2B | $5.2B | $3.7B | $3.9B | $3.9B | $4.2B | $2.9B | $1.5B | $607M | $238M |
| P/E Ratio → | 11.47 | 9.76 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.28 | 3.88 | 4.30 | 2.20 | 3.92 | 5.21 | 10.58 | 9.21 | 6.04 | 3.36 | 4.49 |
| P/B Ratio | — | — | — | — | — | 1951.78 | 8.36 | 4.76 | 4.56 | 4.18 | 3.11 |
| P/FCF | 10.54 | 9.55 | — | — | — | — | — | — | — | — | — |
| P/OCF | 10.40 | 9.43 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.59 | 6.40 | 3.94 | 5.61 | 7.22 | 11.14 | 9.34 | 5.76 | 3.12 | 2.88 |
| EV / EBITDA | 7.71 | 6.94 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 8.06 | 7.32 | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 8.85 | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 95.9% | 92.9% | 93.0% | 93.6% | 94.0% | 95.0% | 96.0% | 95.2% | 97.6% | -42.2% |
| Operating Margin | 49.5% | 49.5% | -37.5% | -46.9% | -64.0% | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% |
| Net Profit Margin | 39.4% | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -216.7% | -81.4% | -53.2% | -50.5% | -57.2% | -68.0% |
| ROA | 29.6% | 29.6% | -20.2% | -34.8% | -30.7% | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.6% |
| ROIC | — | — | -32.2% | -39.9% | -35.0% | -31.6% | -48.8% | -39.7% | -44.9% | -100.1% | -491.7% |
| ROCE | 55.9% | 55.9% | -25.0% | -33.9% | -32.8% | -22.3% | -26.0% | -20.6% | -18.3% | -24.3% | -48.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 882.73 | 0.87 | 0.55 | 0.44 | 0.93 | 0.82 |
| Debt / EBITDA | 0.55 | 0.55 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | 750.80 | 0.44 | 0.07 | -0.21 | -0.30 | -1.12 |
| Net Debt / EBITDA | -0.55 | -0.55 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -0.70 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 5.58 | 5.58 | -1.17 | -4.39 | -5.47 | -5.03 | -6.15 | -18.21 | -9.20 | -5.32 | -15.96 |
Net cash position: cash ($985M) exceeds total debt ($492M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | 2.35 | 2.35 | 2.02 | 1.71 | 1.87 | 4.44 | 3.30 | 1.92 | 3.04 | 5.27 |
| Quick Ratio | 2.27 | 2.27 | 2.31 | 1.97 | 1.65 | 1.84 | 4.37 | 3.22 | 1.83 | 2.90 | 5.27 |
| Cash Ratio | 2.01 | 2.01 | 1.96 | 1.45 | 1.01 | 1.52 | 3.98 | 2.91 | 1.36 | 2.33 | 4.67 |
| Asset Turnover | — | 0.59 | 0.47 | 0.49 | 0.41 | 0.28 | 0.17 | 0.19 | 0.24 | 0.50 | 0.31 |
| Inventory Turnover | 0.90 | 0.90 | 2.47 | 2.14 | 2.05 | 2.04 | 1.01 | 0.63 | 0.79 | 0.43 | — |
| Days Sales Outstanding | — | 38.30 | 71.73 | 62.59 | 81.28 | 74.85 | 67.03 | 66.03 | 93.63 | 75.85 | 110.02 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 8.7% | 10.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 9.5% | 10.5% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $88M | $77M | $75M | $72M | $70M | $66M | $59M | $47M | $39M | $34M |
Regulatory binary outcome risk
According to recent market data, PTCT trades at a TTM P/E of 10.85, a figure that appears artificially compressed by non-recurring royalty monetization events rather than reflecting the company's actual, long-term earnings power or the significant regulatory risks currently facing its primary commercial DMD franchise.
The forward P/E of 95.29 suggests that investors are pricing in a massive contraction in earnings as the one-time gains from the Evrysdi royalty sale roll off the trailing twelve-month window. This valuation gap relative to peers like BioMarin highlights that the market remains uncertain whether to value PTCT as a commercial entity or a speculative R&D platform.
As reported in financial statements, PTCT's gross margins have swung between 45.1% and 98.9% over the last ten quarters, a trend that indicates the company's profitability is driven by episodic accounting gains rather than consistent, sustainable operational efficiency within its rare disease commercial portfolio.
The operating margin of 16.8% in 2026Q1, while positive, appears unsustainable given the high fixed-cost base required for orphan drug commercialization. Investors should monitor whether the company can maintain positive margins without further asset sales, as the current cost structure remains heavily weighted toward R&D.
Based on quarterly data, PTCT's cash conversion cycle has fluctuated significantly, reaching 162 days in 2026Q1, which suggests that the company's reliance on government tenders and international shipments creates lumpy, unpredictable cash inflows that complicate short-term working capital management and operational planning.
The high days inventory outstanding, which peaked at 373 days in 2025Q4, indicates potential challenges in aligning supply chain output with actual patient demand. This inefficiency warrants further investigation, as it ties up capital that could otherwise be deployed toward the company's high-burn R&D pipeline.
As indicated by recent SEC filings, PTCT's cash reserves have declined to $834.0 million in 2026Q1 from a peak of $1.5 billion, signaling that the company's liquidity buffer is being rapidly depleted by ongoing R&D intensity in the absence of further large-scale royalty monetization events.
While the current ratio of 2.44 suggests adequate short-term liquidity, the underlying cash burn remains a concern for long-term solvency. The company's reliance on non-dilutive financing through asset sales appears to be a stop-gap measure rather than a sustainable path to self-funding operations.
The P/E ratio is frequently misapplied to PTCT, as it fails to account for the non-recurring nature of royalty monetization events that have historically distorted the company's net income, leading to a misleading perception of profitability that does not reflect the core commercial franchise's performance.
Analysts should instead focus on EV/Sales or cash burn metrics to better understand the company's true operational health. Using P/E in this context obscures the reality that the company is currently in a capital-intensive development phase where earnings are secondary to the viability of the pipeline.
Includes 30+ ratios · 15 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PTCT stock.
PTC Therapeutics, Inc.'s current P/E ratio is 11.5x. The historical average is 9.8x. This places it at the 100th percentile of its historical range.
PTC Therapeutics, Inc.'s current EV/EBITDA is 7.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 6.9x.
Based on historical data, PTC Therapeutics, Inc. is trading at a P/E of 11.5x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
PTC Therapeutics, Inc. has 95.9% gross margin and 49.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
PTC Therapeutics, Inc.'s Debt/EBITDA ratio is 0.5x, indicating low leverage. A ratio below 2x is generally considered financially healthy.